UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Addition of pazopanib (PZ) to endocrine therapy in hormone resistant
advanced breast cancer (ABC.)
Authors*: Melanie Catherine Majure, Ariadna Gasol Cudós, Austin Nicholas Angelidakis,
Michelle E. Melisko, Ariel R. Karwat, Amy Jo Chien, Andrei Goga, Mark M. Moasser, John W. Park,
Amy N. DeLuca, Hope S. Rugo
Abstract #: 560
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM
Location: Hall A, Poster Board #48
Poster Session: Breast Cancer- HER2/ER
Citation: J Clin Oncol 34, 2016 (suppl; abstr 560)
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage
BC patients, including with UCSFs Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations
with large academic medical centers & consortia in order to expand the novel therapies available to patients.
She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the
Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple
negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial.
At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families
& friends from throughout the bay area.
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648
*UCSF authors in bold
60